Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Moderna ( (MRNA) ) has shared an update.
On May 6, 2026, Moderna’s board amended the company’s by-laws to designate U.S. federal district courts as the exclusive forum for Securities Act litigation, aligning its governance framework with recent changes to Delaware corporate law and potentially streamlining how securities-related disputes are handled. The move clarifies litigation venues for investors and may reduce legal uncertainty around securities claims.
At its May 6, 2026 annual meeting, Moderna shareholders elected Sandra Horning and Abbas Hussain as Class II directors for terms running to 2029 and backed, on a non-binding basis, the company’s executive compensation program. Investors also voted to hold advisory say-on-pay votes annually and ratified Ernst & Young LLP as the independent auditor for 2026, reinforcing existing governance and oversight structures.
The most recent analyst rating on (MRNA) stock is a Buy with a $69.00 price target. To see the full list of analyst forecasts on Moderna stock, see the MRNA Stock Forecast page.
Spark’s Take on MRNA Stock
According to Spark, TipRanks’ AI Analyst, MRNA is a Neutral.
The score is held back primarily by weak financial performance—heavy losses and sustained negative free cash flow—despite a still-solid balance sheet. Technicals also remain bearish with the stock below key moving averages and negative MACD, even as oversold readings suggest pressure may be stretched. The earnings call adds some support through reiterated growth guidance, cost reductions, and regulatory progress, but litigation-related charges and expected cash drawdown keep risk elevated.
To see Spark’s full report on MRNA stock, click here.
More about Moderna
Moderna, Inc. is a biotechnology company focused on developing and commercializing messenger RNA (mRNA) therapeutics and vaccines. The company operates primarily in the biopharmaceutical sector, targeting infectious diseases, oncology, rare diseases and other serious conditions, and plays a significant role in the global market for innovative vaccine and drug platforms.
Average Trading Volume: 7,885,549
Technical Sentiment Signal: Buy
Current Market Cap: $21.57B
Find detailed analytics on MRNA stock on TipRanks’ Stock Analysis page.